Does plasminogen activator inhibitor-1 drive lymphangiogenesis?
The purpose of this study is to explore the function of plasminogen activator inhibitor-1 (PAI-1) during pathological lymphangiogenesis. PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological angiogenesis at least by controlling extracellular proteolysis and by...
Main Authors: | Françoise Bruyère, Laurence Melen-Lamalle, Silvia Blacher, Benoît Detry, Anne Masset, Julie Lecomte, Vincent Lambert, Catherine Maillard, Gunilla Høyer-Hansen, Leif R Lund, Jean-Michel Foidart, Agnès Noël |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2836381?pdf=render |
Similar Items
-
Bone marrow-derived mesenchymal stem cells drive lymphangiogenesis.
by: Ludovic Maertens, et al.
Published: (2014-01-01) -
Bone Marrow-derived Myofibroblasts Are the Providers of Pro-invasive Matrix Metalloproteinase 13 in Primary Tumor
by: Julie Lecomte, et al.
Published: (2012-10-01) -
Effects of adenosine on lymphangiogenesis.
by: Bénédicte Lenoir, et al.
Published: (2014-01-01) -
Digging deeper into lymphatic vessel formation <it>in vitro </it>and <it>in vivo</it>
by: Thiry Marc, et al.
Published: (2011-06-01) -
Contribution à l'étude de la protéolyse au cours de la lymphangiogenèse/Contribution to the study of proteolysis implicated in the lymphangiogenesis.
by: Bruyere, Françoise
Published: (2009)